Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

2.0K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

594
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
594
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

490
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
490
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

1.2K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.2K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.5K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

631
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
631

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Myocardial Oedema in Heart Failure with Preserved Ejection Fraction: Preliminary Findings from the NETDiamond Cohort.

European journal of heart failure·2026
Same author

Myocardial expression of <i>ADGRL4</i> and <i>AQP7</i> is related to regression of left ventricular hypertrophy after aortic valve replacement in a sex-dependent manner.

American journal of physiology. Heart and circulatory physiology·2026
Same author

International Union of Angiology (IUA) Consensus Document on Enhanced Recovery after Surgery (ERAS) in Vascular Surgery.

International angiology : a journal of the International Union of Angiology·2026
Same author

Artificial Intelligence in Pulmonary Endoscopy: Current Evidence, Limitations, and Future Directions.

Journal of imaging·2026
Same author

Correction to: Myosin-Inhibitor Mavacamten Acutely Enhances Cardiomyocyte Diastolic Compliance in Heart Failure With Preserved Ejection Fraction.

Circulation. Heart failure·2026
Same author

Oral-heart axis from pregnancy and postpartum: maternal oral microbiota relates with cardiac reverse remodeling.

Journal of oral microbiology·2026

Related Experiment Video

Updated: Apr 20, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.8K

Levosimendan: The current situation and new prospects.

Nuno Moreno1, Marta Tavares-Silva1, André P Lourenço1

  • 1Departamento de Fisiologia e Cirurgia Cardiotorácica, Faculdade de Medicina da Universidade do Porto, Porto, Portugal.

Revista Portuguesa De Cardiologia : Orgao Oficial Da Sociedade Portuguesa De Cardiologia = Portuguese Journal of Cardiology : an Official Journal of the Portuguese Society of Cardiology
|December 3, 2014
PubMed
Summary

Levosimendan, a heart failure drug, improves hemodynamics but its long-term survival benefits remain unclear. This review summarizes current knowledge and future uses of this inotropic agent.

Keywords:
Heart failureInotropesInotrópicosInsuficiência cardíacaLevosimendan

More Related Videos

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

11.1K
Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

7.6K

Related Experiment Videos

Last Updated: Apr 20, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.8K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

11.1K
Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

7.6K

Area of Science:

  • Pharmacology
  • Cardiology
  • Drug Development

Background:

  • Levosimendan is a pyridazinone-dinitrile derivative.
  • It exhibits positive inotropic and vasodilatory effects, enhancing myocardial performance.
  • Previous studies show improved hemodynamics and clinical course, but prognostic impact is uncertain.

Purpose of the Study:

  • To review current knowledge on levosimendan.
  • To explore its potential in various clinical conditions beyond acute heart failure.
  • To present future prospects for levosimendan's application.

Main Methods:

  • Literature review of randomized studies and clinical trials.
  • Analysis of pharmacological properties and clinical effects.
  • Synthesis of existing data on levosimendan's efficacy and safety.

Main Results:

  • Levosimendan demonstrates beneficial effects on myocardial performance.
  • Hemodynamic improvements and enhanced clinical course are noted.
  • The effect of levosimendan on patient prognosis requires further investigation.

Conclusions:

  • Levosimendan is a valuable agent for myocardial performance.
  • Its unclear impact on prognosis currently limits broader clinical use.
  • Further research is needed to establish its role in diverse cardiovascular conditions and long-term outcomes.